SIRT1 and Alzheimer disease: Given that DNA methylation plays a dominant role in rebuilding the landscape of histone modifications and in REST depletion, it is tempting to propose that DNMTs, MeCP2, and SIRT1 may be potential drug candidates for AD therapy.